1. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14: 1157-1174. [PubMed]

2. Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis : expanding the concept of “no better explanation.” Lancet Neurol. 2006;5:841-852. [PubMed]

3. Minneboo A, Barkhof F, Polman CH, Uitehaag BM, Know DL, Castelijns JA. Intratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004;61:217-221. [PubMed]

4. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain. 1993;116:135-146. [PubMed]

5. Tintoré M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinical isolated syndromes. Neurology. 2006;67:968-972. [PubMed]

6. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72:800-805. [PubMed]

7. Beck RW, Gal RL, Bhatti MT, Brodsky MC, et al; Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137(1):77-83. [PubMed]

8. O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998;121 (Pt 3):495-503. [PubMed]

9. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:158-164. [PubMed]

10. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008 Mar;131 (Pt 3):808-17. [PubMed]

11. Kappos L et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389-397. [PubMed]

12. Kappos L et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-1249. [PubMed]

13. Freedman MS, Kappos L, Polman CH, et al. Impact of early interferon beta-1b treatment on disease evolution over five years in patients with a first event suggestive of multiple sclerosis. Presented at the World Congress on Treatment and Research in Multiple Sclerosis, September 17-20, 2008, Montreal, Canada.

14. Morimatsu M. Recurrent ADEM or MS? Int Med. 2004;43:647-648. [PubMed]

15. Hartung H-P, Grossman RI. ADEM. Distinct disease or part of the MS spectrum? Neurology. 2001;56:1257-1260. [PubMed]

16. Banwell B, Shroff M, Ness JM, et al. MRI features of pediatric multiple sclerosis. Neurology. 2007;68(suppl 2):S46-S53. [PubMed]

17. Krupp LB, Banwell B, Tenembaum S, for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68(suppl 2):S7-S12. [PubMed]

18. Hunter SB, Ballinger WE Jr, Rubin JJ. Multiple sclerosis mimicking primary brain tumor. Arch Pathol Lab Med. 1987;111:464-468. [PubMed]

19. Johnson MD, Lavin P, Whetsell WO Jr. Fulminant monophasic multiple sclerosis, Marburg’s type. J Neurol Neurosurg Psychiatry. 1990;53:918-921. [PubMed]

20. Kepes JJ. Large focal tumor-like deyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encaphlomyelitis? A study of 31 patients. Ann Neurol. 1993;33:18-27. [PubMed]

21. Moore GRW, Neumann PE, Suzuki K, Lijtmaer HN, Traugott U, Raine CS. Balo’s concentric sclerosis: new observations on lesion development. Ann Neurol. 1985;17:604-611. [PubMed]

22. Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: changing concepts. J Neuroimmunol. 2007;187:126-138. [PubMed]

23. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815. [PubMed]

24. Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic’s neuromyelitis optica. J Neurol. 2004;251:47-52. [PubMed]

25. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107-1114. [PubMed]

26. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F. Revised diagnostic criteria for neuromyelitis optima (NMO). Application in a series of suspected patients. J Neurol. 2007;254:1233-1237. [PubMed]

27. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66:1485-1489. [PubMed]

28. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130(Pt 5):1235-1243. [PubMed]

29. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007;68:1076-1077. [PubMed]

30. Filippi M, Rocca MA, Moiola L, et al. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic’s neuromyelitis optica. Neurology. 1999;53:1705-1710. [PubMed]